Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 May 5;2(2):ofv040.
doi: 10.1093/ofid/ofv040. eCollection 2015 Apr.

Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial

Edgar Turner Overton  1 , Jack Stapleton  2 , Ian Frank  3 , Shawn Hassler  4 , Paul A Goepfert  1 , David Barker  5 , Eva Wagner  6 , Alfred von Krempelhuber  7 , Garth Virgin  8 , Thomas Peter Meyer  6 , Jutta Müller  6 , Nicole Bädeker  6 , Robert Grünert  6 , Philip Young  6 , Siegfried Rösch  6 , Jane Maclennan  6 , Nathaly Arndtz-Wiedemann  6 , Paul Chaplin  6
Affiliations

Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial

Edgar Turner Overton et al. Open Forum Infect Dis. .

Erratum in

Abstract

Background. First- and second-generation smallpox vaccines are contraindicated in individuals infected with human immunodeficiency virus (HIV). A new smallpox vaccine is needed to protect this population in the context of biodefense preparedness. The focus of this study was to compare the safety and immunogenicity of a replication-deficient, highly attenuated smallpox vaccine modified vaccinia Ankara (MVA) in HIV-infected and healthy subjects. Methods. An open-label, controlled Phase II trial was conducted at 36 centers in the United States and Puerto Rico for HIV-infected and healthy subjects. Subjects received 2 doses of MVA administered 4 weeks apart. Safety was evaluated by assessment of adverse events, focused physical exams, electrocardiogram recordings, and safety laboratories. Immune responses were assessed using enzyme-linked immunosorbent assay (ELISA) and a plaque reduction neutralization test (PRNT). Results. Five hundred seventy-nine subjects were vaccinated at least once and had data available for analysis. Rates of ELISA seropositivity were comparably high in vaccinia-naive healthy and HIV-infected subjects, whereas PRNT seropositivity rates were higher in healthy compared with HIV-infected subjects. Modified vaccinia Ankara was safe and well tolerated with no adverse impact on viral load or CD4 counts. There were no cases of myo-/pericarditis reported. Conclusions. Modified vaccinia Ankara was safe and immunogenic in subjects infected with HIV and represents a promising smallpox vaccine candidate for use in immunocompromised populations.

Keywords: HIV infection; MVA; immunocompromised; smallpox; vaccination.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Disposition of subjects and data sets analyzed. Of 1108 screened volunteers, 581 subjects were assessed eligible for enrolment, 579 subjects were allocated to 1 of 4 study groups, and all 579 subjects received at least 1 vaccination (full analysis set [FAS]). One hundred eighty-five subjects were excluded from the per-protocol analysis set ([PPS] n = 394). The active phase of the study is up to the visit for the last vaccination and the follow-up (FU) phase is at least 26 weeks after last vaccination. Only 164 from 501 subjects came to an on-site visit for the Follow-up, for 337 of 501 subjects the safety-relevant information was gathered by telephone. For all other subjects, the safety-relevant information was gathered by telephone FU. In case any serious safety issues were detected via telephone, the subject was asked to appear for an onsite visit. Abbreviation: vacc., vaccinia.
Figure 2.
Figure 2.
Kinetics of humoral immune responses after 2 vaccinations with Modified vaccinia Ankara-Bavarian Nordic. Total and neutralizing antibody responses were analyzed by enzyme-linked immunosorbent assay ([ELISA] A and B) and plaque reduction neutralization test ([PRNT] C and D) using the Per Protocol Set. Abbreviation: GMT, geometric mean titer.
Figure 3.
Figure 3.
Kinetics of humoral immune responses after 2 vaccinations with Modified vaccinia Ankara-Bavarian Nordic. Total and neutralizing antibody responses were analyzed by enzyme-linked immunosorbent assay ([ELISA] A and B) and plaque reduction neutralization test ([PRNT] C and D) using the Full Analysis Set. Abbreviation: GMT, geometric mean titer.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Breman JG, Arita I. The confirmation and maintenance of smallpox eradication. N Engl J Med 1980; 303:1263–73. - PubMed
    1. Mayr A. Smallpox vaccination and bioterrorism with pox viruses. Comp Immunol Microbiol Infect Dis 2003; 26:423–30. - PubMed
    1. Gaudioso J, Brooks TF, Furukawa, Lavanchy DO, Friedman D, Heegaard ED. Likelihood of Smallpox Recurrence. J Bioterr Biodef 2011; 2:106 10.4172/2157-2526.1000106. - DOI
    1. Goldstein JA, Neff JM, Lane JM, Koplan JP. Smallpox vaccination reactions, prophylaxis, and therapy of complications. Pediatrics 1975; 55:342–7. - PubMed
    1. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J Infect Dis 1970; 122:303–9. - PubMed